ClinicalTrials.gg

TargetBeta

IL18

interleukin 18 · also IGIF, IL1F4, IL-1g, IL-18 · Interleukins

6 programs in company-led studies act on IL18, from 4 companies: 0 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
arumakimigNovartisphase 273 runningIL1Bthe company's pipeline
aletekitugruleGlaxoSmithKlinephase 292 running–ChEMBL
camoteskimabruleApollo Therapeuticsphase 251 running–NCIt
GHZ339Novartisphase 211 runningIL13the company's pipeline
BLN-481ruleBeeline Medicinesphase 111 running–the studies' text
GSK4528287GlaxoSmithKlinephase 111 runningIL23Athe company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.